The Company has signed a consulting agreement with Dr. Lars Bärfacker, an experienced medicinal chemist and former Principal Research Scientist at Bayer AG, to support aspects of NurExone’s European scientific and strategic initiatives. Dr. Bärfacker has more than two decades of experience in drug discovery and innovation and has contributed to the discovery of several clinical compounds, including Finerenone (Kerendia®), now approved for the treatment of cardiorenal diseases.
NurExone CEO, Dr. Lior Shaltiel, noted: “Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications, including his experience at Bayer. His perspective will be valuable as NurExone continues advancing its regenerative medicine platform globally, particularly in Europe.”